FI116881B - Farmaceutiska kompositioner, som möjliggör fördröjd frigörelse av trimetazidin efter oral dosering - Google Patents

Farmaceutiska kompositioner, som möjliggör fördröjd frigörelse av trimetazidin efter oral dosering Download PDF

Info

Publication number
FI116881B
FI116881B FI951357A FI951357A FI116881B FI 116881 B FI116881 B FI 116881B FI 951357 A FI951357 A FI 951357A FI 951357 A FI951357 A FI 951357A FI 116881 B FI116881 B FI 116881B
Authority
FI
Finland
Prior art keywords
pharmaceutical composition
composition according
trimethazidine
sustained release
trimetazidine
Prior art date
Application number
FI951357A
Other languages
English (en)
Finnish (fi)
Other versions
FI951357A (sv
FI951357A0 (sv
Inventor
De Barochez Bruno Huet
Alain Cuine
Patrick Genty
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of FI951357A0 publication Critical patent/FI951357A0/sv
Publication of FI951357A publication Critical patent/FI951357A/sv
Application granted granted Critical
Publication of FI116881B publication Critical patent/FI116881B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (9)

1. En farmaceutisk sammansättning för fördröjd fr: av trimetazidin eller nägot av dess farmaceutiskt 5 bara salter, kännetecknad därav, att den fördröjd; ringen av trimetazidin kontrolleras med hjälp av s servoarsystem, väri en blandning, som innehäller e ten oloslig polymer och en mjukgörare, är i form ; film, som täcker tabletter eller minigranuler, viJ 10 häller trimetazidin eller nägot av dess additionss med en farmaceutiskt godtagbar syra, och väri mju} är en annan an en hydrerad oija.
2. Farmaceutisk sammansättning enligt patentkravet 15 netecknad därav, att trimetazidin är i dihydröklöi
3. Farmaceutisk sammansättning enligt patentkravet netecknad därav, att reservoarsystemet omfattar er voartablett. 20
4. Farmaceutisk sammansättning enligt patentkravet netecknad därav, att reservoarsystemet omfattar er ; ;\ tinreservoarkapsel, som innehäller belagda minigrs *«· # «4 4 : V
5. Farmaceutisk sammansättning enligt patentkravet * netecknad därav, att den använda polymeren är etyl *;;/ sa i form av en organisk lösning eller en vattendi 4 4 * 4 · # * on. • « : 30 6. Farmaceutisk sammansättning enligt patentkravet ί netecknad därav, att den använda polymeren är ett
8. Farmaceutisk sammansättning enligt patentkravet netecknad därav, att mjukgöraren är dibutylsebakat
9. Farmaceutisk sammansättning enligt patentkravet 5 netecknad därav, att den möjliggör en kontrollerad jämn frigöring av trimetazidin frän början av intä och ätminstone for en tidsperiod av 16 timmar.
10. Farmaceutisk sammansättning enligt patentkrave 10 kannetecknad därav, att den är användbar i profylä: angina pectoris anfall, under chorioretinalanfall, under behandling av svindel av vaskulärt ursprung. ·« • 4 • 94 • i « « 4 • · ♦ ··· 4 9Ψ 9 # I · f » • · • * 9 · • « f < I i«« « • 9» 9 9 9 9 9 9 9 9 9 9 9 9 9 9 4 949 4 944 4 4
FI951357A 1994-03-24 1995-03-22 Farmaceutiska kompositioner, som möjliggör fördröjd frigörelse av trimetazidin efter oral dosering FI116881B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9403434 1994-03-24
FR9403434A FR2717687B1 (fr) 1994-03-24 1994-03-24 Compositions pharmaceutiques permettant la libération prolongée de trimétazidine après administration par voie orale.

Publications (3)

Publication Number Publication Date
FI951357A0 FI951357A0 (sv) 1995-03-22
FI951357A FI951357A (sv) 1995-09-25
FI116881B true FI116881B (sv) 2006-03-31

Family

ID=9461361

Family Applications (1)

Application Number Title Priority Date Filing Date
FI951357A FI116881B (sv) 1994-03-24 1995-03-22 Farmaceutiska kompositioner, som möjliggör fördröjd frigörelse av trimetazidin efter oral dosering

Country Status (15)

Country Link
EP (1) EP0673649B1 (sv)
JP (1) JP3017040B2 (sv)
CN (1) CN1056057C (sv)
AT (1) ATE216583T1 (sv)
AU (1) AU684893B2 (sv)
CA (1) CA2145248C (sv)
DE (1) DE69526467T2 (sv)
DK (1) DK0673649T3 (sv)
ES (1) ES2176296T3 (sv)
FI (1) FI116881B (sv)
FR (1) FR2717687B1 (sv)
NO (1) NO306450B1 (sv)
NZ (1) NZ270791A (sv)
PT (1) PT673649E (sv)
ZA (1) ZA952418B (sv)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2802424B1 (fr) * 1999-12-17 2002-02-15 Adir Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale
PT1195160E (pt) * 2000-10-05 2009-12-07 Usv Ltd Composições farmacêuticas de trimetazidina de libertação sustentada e método para a sua preparação
FR2818549B1 (fr) * 2000-12-26 2003-02-07 Servier Lab Composition pharmaceutique solide thermoformable pour la liberation controlee de trimetazidine
EP1448173A2 (en) * 2001-11-21 2004-08-25 Themis Laboratories Private Limited A process for manufacture of a sustained release pharmaceutical composition containing microbeads of trimetazidine dihydrochloride
FR2885807B1 (fr) * 2005-05-18 2008-05-16 Mg Pharma Composition pharmaceutique solide a liberation prolongee de 1-(2,3,4-trimethoxybenzyl) piperazine, et procede de preparation
WO2007116243A2 (en) * 2006-04-10 2007-10-18 Mintails Limited Method for treating fibromyalgia and related conditions
EP2200591A2 (en) 2007-09-11 2010-06-30 Ranbaxy Laboratories Limited Controlled release pharmaceutical dosage forms of trimetazidine
EP2389167A2 (en) 2009-01-20 2011-11-30 Micro Labs Limited Modified release solid pharmaceutical compositions of trimetazidine and process thereof
ES2567722T3 (es) * 2009-01-30 2016-04-26 Lupin Limited Composiciones farmacéuticas de trimetazidina
TR201001902A2 (tr) 2010-03-12 2011-04-21 Ali̇ Rai̇f İlaç Sanayi̇ Ve Ti̇caret A.Ş. Uzatılmış salınımlı trimetazidin tablet
ES2508490T3 (es) 2010-05-04 2014-10-16 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Formulación de trimetazidina con diferentes perfiles de liberación
EP2386302A1 (en) 2010-05-11 2011-11-16 Ranbaxy Laboratories Limited A controlled release pharmaceutical dosage form of trimetazidine and processes for the preparation thereof
BG1345U1 (bg) * 2010-05-20 2010-08-31 "Адифарм" Ад Лекарствена форма с изменено освобождаване
EP2491930A1 (en) 2011-02-25 2012-08-29 Deva Holding Anonim Sirketi Pharmaceutical combination of betahistine and trimetazidine
CN102133195A (zh) * 2011-03-17 2011-07-27 王国栋 盐酸曲美他嗪的缓控释微丸及其制备方法
CN102319225B (zh) * 2011-09-23 2013-04-03 广州白云山光华制药股份有限公司 一种盐酸曲美他嗪缓释片及其制备方法
FR2986431B1 (fr) * 2012-02-03 2017-03-17 Servier Lab Composition pharmaceutique a liberation prolongee de trimetazidine, son procede de fabrication et son utilisation dans des traitements therapeutiques
CN102764261A (zh) * 2012-07-30 2012-11-07 沈阳药科大学 口服控制盐酸曲美他嗪释放的组合物及其制备方法
CN103565751A (zh) * 2013-10-17 2014-02-12 广州帝奇医药技术有限公司 一种长效缓释微丸及其制备方法
US20190381034A1 (en) * 2018-06-14 2019-12-19 Ming Fang Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases
CN110237053A (zh) * 2019-07-26 2019-09-17 湖北欣泽霏药业有限公司 一种盐酸曲美他嗪缓释微丸及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2490963B1 (fr) * 1980-09-30 1986-04-18 Science Union & Cie Nouvelle composition therapeutique a action anti-ischemique contenant de la trimethoxy 2, 3, 4-benzyl 1-piperazine
DE3686275T2 (de) * 1985-01-11 1993-03-18 Teijin Ltd Praeparate mit verzoegerter freisetzung.
JPH0625055B2 (ja) * 1985-03-18 1994-04-06 日本ケミフア株式会社 持続性錠剤
US5260066A (en) * 1992-01-16 1993-11-09 Srchem Incorporated Cryogel bandage containing therapeutic agent
US5417983A (en) * 1992-02-19 1995-05-23 Sagami Chemical Research Center Drug release controlling material responsive to changes in temperature

Also Published As

Publication number Publication date
FR2717687A1 (fr) 1995-09-29
DE69526467T2 (de) 2002-12-05
NO951110D0 (no) 1995-03-23
DE69526467D1 (de) 2002-05-29
AU1502995A (en) 1995-10-05
EP0673649B1 (fr) 2002-04-24
CN1124140A (zh) 1996-06-12
PT673649E (pt) 2002-08-30
ATE216583T1 (de) 2002-05-15
CN1056057C (zh) 2000-09-06
JPH07258086A (ja) 1995-10-09
NO951110L (no) 1995-09-25
CA2145248C (fr) 2004-01-06
CA2145248A1 (fr) 1995-09-25
DK0673649T3 (da) 2002-08-05
ZA952418B (en) 1995-12-18
EP0673649A1 (fr) 1995-09-27
JP3017040B2 (ja) 2000-03-06
NO306450B1 (no) 1999-11-08
FI951357A (sv) 1995-09-25
ES2176296T3 (es) 2002-12-01
FI951357A0 (sv) 1995-03-22
FR2717687B1 (fr) 1996-06-14
NZ270791A (en) 1996-07-26
AU684893B2 (en) 1998-01-08

Similar Documents

Publication Publication Date Title
FI116881B (sv) Farmaceutiska kompositioner, som möjliggör fördröjd frigörelse av trimetazidin efter oral dosering
RU2095054C1 (ru) Твердая лекарственная форма для орального введения
FI78835B (fi) Foerfarande foer framstaellning av en ny dipyridamol-retardform.
DK175578B1 (da) Farmaceutisk præparat med kontrolleret frigivelseshastighed
JP6687248B2 (ja) 回腸−空腸薬物送達用組成物
SU1706373A3 (ru) Способ получени средства с регулируемым высвобождением активного соединени
TWI262079B (en) Controlled release Galantamine formulation
US4578264A (en) Retard form of pharmaceuticals with insoluble porous diffusion coatings
US8747898B2 (en) Controlled release oral dosage form
FI87990C (sv) Förfarande för framställning av en farmaceutisk komposition i en enhet sdosform
JPH0530804B2 (sv)
BRPI0621397A2 (pt) tabletes de liberação prolongada de metoprolol succinato e seus processos de preparação
WO2005120468A1 (en) Multi-layered controlled-release methylphenidate pellet
BRPI0615014A2 (pt) composição farmacêutica sólida compreendendo 1-(4-cloroanilino)-4-(4-piridilmetil)ftalazina e um modificador de ph e uso da mesma
US20120003307A1 (en) Levetiracetam controlled release composition
BG64764B1 (bg) Многочастична фармацевтична форма със забавено и пулсационно освобождаване и метод за получаването й
US4968506A (en) Pharmaceutical dosage with core of N-acetyl cystein
GB2098867A (en) Sustained release pharmaceutical composition
EP2386302A1 (en) A controlled release pharmaceutical dosage form of trimetazidine and processes for the preparation thereof
JPH09504779A (ja) α−アドレノリセプタ遮断剤用薬剤移送組成物
WO2020111089A1 (ja) 医薬組成物
EP1434570B1 (en) Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline
JPS60228410A (ja) 持続性製剤
KR840000692B1 (ko) 디피리다몰 서방출형 제제의 제조방법
MC MK et al. preparation thereof

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 116881

Country of ref document: FI

MA Patent expired